This document presents the Movement Disorder Society Clinical Diagnostic Criteria for
Parkinson's disease (PD). The Movement Disorder Society PD Criteria are intended for use in …

The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational,
international, multi-center study designed to identify PD progression biomarkers both to improve …

Importance Early identification of Alzheimer disease (AD) is important for clinical management
and affords the opportunity to assess potential disease-modifying agents in clinical trials. …

This article describes research criteria and probability methodology for the diagnosis of
prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD …

Background Accurate diagnosis and early detection of complex diseases, such as Parkinson's
disease, has the potential to be of great benefit for researchers and clinical practice. We …

Background Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson’s
disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is …

Background: LMTM is being developed as a treatment for AD based on inhibition of tau
aggregation. Objectives: To examine the efficacy of LMTM as monotherapy in non-randomized …

Background and Objectives The PARS (Parkinson Associated Risk Syndrome) study was
designed to test whether screening for hyposmia followed by dopamine transporter imaging …

Importance Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific
tau aggregates establish the neuropathologic diagnosis of definite PSP post mortem. Future …

It is currently widely acknowledged that the natural history of PD includes a preclinical phase,
and there are increasing efforts to identify markers that would allow the identification of …